Ignite Creation Date:
2024-05-06 @ 3:56 PM
Last Modification Date:
2025-12-17 @ 9:38 AM
Study NCT ID:
NCT04800224
Status:
None
Last Update Posted:
2022-05-13 00:00:00
First Post:
2021-03-12 00:00:00
Brief Title:
Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)
Sponsor:
DOr Institute for Research and Education
Organization:
D'Or Institute for Research and Education
Study Overview
Official Title:
The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial
Status:
None
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BeeCovid2
Brief Summary:
To evaluate the efficacy and safety of oral propolis as an adjunct treatment for SARS-CoV-2 infection, we designed a randomized, double-blind, placebo-controlled trial (Bee-Covid2) (The Use of Brazilian Green Propolis Extract (EPP-AF®) in Patients Affected by COVID-19).
Detailed Description:
To evaluate the efficacy and safety of oral propolis as an adjunct treatment for SARS-CoV-2 infection we designed a randomized double-blind placebo-controlled trial Bee-Covid2 The Use of Brazilian Green Propolis Extract EPP-AF in Patients Affected by COVID-19
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None